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Abstract
Chaperones TAPBPR and tapasin associate with class-I major histocompatibility complexes 
(MHC-I) to promote optimization (editing) of peptide cargo. Here, we use solution NMR to 
investigate the mechanism of peptide exchange. We identify TAPBPR-induced conformational 
changes on conserved MHC-I molecular surfaces, consistent with our independently determined 
X-ray structure of the complex. Dynamics present in the empty MHC-I are stabilized by TAPBPR, 
and become progressively dampened with increasing peptide occupancy. Incoming peptides are 
recognized according to the global stability of the final pMHC-I product, and anneal in a native-
like conformation to be edited by TAPBPR. Our results demonstrate an inverse relationship 
between MHC-I peptide occupancy and TAPBPR binding affinity, where the lifetime and 
structural features of transiently bound peptides controls the regulation of a conformational switch, 
located near the TAPBPR binding site, which triggers TAPBPR release. These results suggest a 
similar mechanism for the function of tapasin in the peptide-loading complex.
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INTRODUCTION
A protective immune response against endogenous antigens generated from infectious 
agents or tumors is elicited through interactions between αβ T cell receptors (TCRs) on 
CD8+ cytotoxic T cells and peptide-loaded major histocompatibility complex class I 
(pMHC-I) molecules displayed on the surface of antigen-presenting cells 1. Properly 
conformed pMHC-I is assembled by an intracellular pathway in which loading of the MHC-
I nascent chain with high-affinity peptides dictates complex stability, cell surface lifetime, 
and immunogenicity 2. Peptide loading and editing is orchestrated by molecular chaperones 
tapasin and TAPBPR (TAP-binding protein related), which function as peptide exchange 
catalysts that influence the repertoire of MHC-I displayed antigens at the cell surface 3–7. 
These chaperones have been linked to human disease where altered expression results in 
deregulation of the peptide presentation pathway and dampening of T cell-mediated immune 
responses in the context of cancer, infections, and autoimmune diseases 8–12. A number of 
studies have gleaned key insights into the peptide editing functions of tapasin (a key 
component of the peptide-loading complex) and TAPBPR 13–15. While sharing a common 
function as MHC-I peptide editors, recent data suggest tapasin and TAPBPR perform 
discrete roles in the cell 15. This is supported by the finding that TAPBPR is unable to 
compensate for tapasin in situ 16,17, and elicits distinct effects on the repertoire of displayed 
peptides 5, possibly due to differences in MHC-I allelic dependencies between the two 
chaperones 13. Furthermore, while tapasin is associated with the transporter associated with 
antigen processing (TAP) in the endoplasmic reticulum (ER), TAPBPR does not interact 
with either TAP or ERp57 16 and lacks an ER retention motif, thus its localization is not 
restricted to the ER. As a result, TAPBPR is also found in the Golgi, and can chaperone 
MHC-I molecules farther along the trafficking pathway 16. Recently, TAPBPR has been 
suggested to perform an additional quality control in the peptide loading pathway by 
assisting in MHC-I re-glycosylation and consequent recycling of improperly conformed 
molecules to the ER 18. Despite these important insights, the molecular basis of the peptide-
editing function of TAPBPR (and tapasin) remains incompletely characterized.
Recently, two X-ray structures of peptide-deficient complexes between TAPBPR and the 
murine MHC-I molecules H2-Dd and H2-Db were determined at resolutions of 3.4 Å and 3.3 
Å, respectively 19,20. These studies propose a direct role for a ~3 Å widening of the MHC-I 
groove at the conserved α2-1 helix, induced by TAPBPR, in promoting the release of non-
optimal peptides. Complementary biophysical data and molecular dynamics (MD) 
simulations have suggested a conformational switch role for the α2-1 helix “latch” during 
peptide exchange, both with and without chaperones 13,21,22. Furthermore, a 5.8 Å cryo-
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electron microscopy (cryoEM) model of the tapasin/MHC-I assembly 23 showed a consistent 
chaperone/MHC-I recognition mechanism. However, important mechanistic details 
concerning recognition of incoming peptides by the chaperoned groove are difficult to 
visualize crystallographically, or by cryoEM. Recent advances in solution nuclear magnetic 
resonance (NMR) spectroscopy have enabled the characterization of high molecular weight 
protein assemblies of considerable size and dynamic complexity 24. Here, we utilize these 
methods to explore the interaction of TAPBPR with MHC-I molecules of varying peptide 
occupancies, and provide new insights towards understanding how TAPBPR “edits” the 
peptide repertoire. Our results suggest a peptide exchange mechanism in which a transient 
pMHC-I/TAPBPR intermediate governs the selection of high-affinity peptides. Based on a 
range of biophysical data, we propose a model for chaperone release through negative 
allosteric coupling between non-overlapping chaperone and peptide binding sites along both 
ends of the MHC-I groove. Insights derived from our data provide a molecular blueprint for 
engineering novel molecular chaperones with desired specificities to promote peptide 
exchange both in vitro and in vivo.
RESULTS
Dynamics of pMHC-I in solution
To examine dynamic MHC-I regions and their putative role in peptide exchange13,21, we 
used solution NMR to characterize flexibility in a 45 kDa MHC-I molecule comprised of a 
murine H2-Dd heavy chain refolded with human light chain (hβ2m)25 and a high-affinity 
peptide (P18-I10, RGPGRAFVTI) derived from the HIV gp160 envelope protein 6. We first 
recorded 15N TROSY R1 and R2 relaxation rates, in conjunction with 15N-{1H} NOE values 
26
. We find several regions of increased mobility on H2-Dd, in particular the β1-β2 loop, β3-
β4 loop, α3 domain and C-terminus, which show decreased 15N-{1H} NOE, R2 values and 
increased R1 values (Fig. 1A). We additionally acquired 1H-13C multiple-quantum Carr-
Purcell-Meiboom-Gill (CPMG) relaxation dispersion experiments, in which the resonances 
of methyl groups undergoing conformational exchange in the μs-ms timescale exhibit 
changes in their effective relaxation rate (R2,eff) as a function of the frequency of the 
refocusing pulse (νCPMG) 27. In total, conformational exchange is observed for 14 AILV 
methyl groups on H2-Dd and 8 on hβ2m (Fig. 1B, C). For H2-Dd, sites undergoing dynamics 
are found on the pleated β-sheet of the groove, at the interface with hβ2m, the C-terminal 
end of the α2-1 helix, and within the α3 domain (Fig. 1B, D). For hβ2m, dynamic sites are 
localized at the interface with H2-Dd, suggesting the presence of restricted inter-domain 
motions in the pMHC-I (Fig. 1C, D). H2-Dd groove sites undergoing conformational 
exchange are localized rather than spanning the entire groove, suggesting sampling of 
alternative local conformations, rather than exchange with a peptide-free form (Fig. 1D, E). 
Notably, we find that MHC-I regions of increased flexibility correlate with residues required 
for TAPBPR association (Supplementary Fig. 1), supporting a direct role for dynamics in 
driving recognition of peptide-editing chaperones 13,21.
TAPBPR recognition of a peptide-loaded MHC-I molecule
To evaluate the propensity for TAPBPR to bind H2-Dd molecules with distinct peptide 
occupancies, we used size exclusion chromatography (SEC) 6, to find that TAPBPR forms a 
McShan et al. Page 3
Nat Chem Biol. Author manuscript; available in PMC 2019 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
high-affinity complex with either peptide-deficient H2-Dd (Supplementary Fig. 2), partially 
loaded RGPGC/H2-Dd S73C or fully-loaded P18-I10/H2-Dd (Supplementary Fig. 3A–C). 
Subsequent characterization by NMR reveals a tight complex between pMHC-I 
(Supplementary Fig. 4) and TAPBPR, in which chemical exchange between the free and 
bound states is slow on the chemical shift timescale. We observe two types of effects on the 
H2-Dd and hβ2m backbone amide and AILV methyl resonances upon TAPBPR binding: i) 
chemical shift deviations (CSDs), indicating a change in the local magnetic environment, 
and ii) conformational exchange-induced line broadening leading to reduced peak intensity 
ratios (I/I0), suggesting changes in μs-ms timescale dynamics (Supplementary Fig. 5, 
Supplementary Fig. 6 and Supplementary Fig. 7). Mapping effects onto the pMHC-I 
structure reveals affected H2-Dd sites on the α1 helix, α2 helix, the pleated β-sheet on the 
floor of the groove and on the α3 domain at the CD8 binding site (Supplementary Fig. 5A, B 
and Supplementary Fig. 6A, B and Supplementary Fig. 7A, C). For hβ2m, we identify a 
continuous molecular surface located at the interface with the H2-Dd α3 domain 
(Supplementary Fig. 5C, D, Supplementary Fig. 6C, D and Supplementary Fig. 7B, D).
To quantitatively characterize binding under conditions where peptide dissociation from the 
complex is minimal, we titrated TAPBPR into a 100 μM pMHC-I sample (labeled at the 
heavy chain) and performed a rigorous NMR line shape analysis for the resonances of nine 
methyl probes spanning both TAPBPR binding sites (Fig. 2A–D). The two regions are 
simultaneously and cooperatively engaged by TAPBPR with globally fitted Kd and koff 
values of 32 μM and 2.9 s−1, respectively (Supplementary Fig. 5E, F and Supplementary Fig. 
6E, F, Supplementary Fig. 10). Notwithstanding our observation of a substantial interaction 
between TAPBPR and H2-Dd loaded with a high-affinity peptide, recognition of peptide-
loaded molecules shows a strong MHC allelic dependency. No TAPBPR binding could be 
detected in experiments using three additional peptide-loaded class I HLA (human leukocyte 
antigen) molecules, either by SEC (HLA-B*15:01, HLA-B*27:02) or by NMR (HLA-
A01:01), suggesting that if there is such an interaction it must be extremely transient (koff ≫ 
3 s−1). (Supplementary Fig. 8, Supplementary Fig. 9).
Finally, whether N-linked glycosylation of conserved Asn residues on the MHC-I modulates 
chaperone association (outside of a protein localization to the PLC) remains unclear 18. 
Towards further exploration of a potential structural basis for such an interaction we 
modeled the Glc1Man9GlcNAc2 glycan which is recognized by calreticulin 28, using the 
putative N-glycan acceptor sites 29 on H2-Dd or H2-Db in the two X-ray MHC-I/TAPBPR 
structures. Although we find no clear overlap between the glycans and TAPBPR by 
structural modeling (Supplementary Fig. 11), this important aspect of MHC-I recognition by 
chaperones remains to be addressed in future experiments.
Comparison of solution NMR mapping with X-ray structures
While NMR experiments were underway, the X-ray structures of the H2-Dd S73C/β2m/
TAPBPR 20 and H2-Db/β2m/TAPBPR 19 complexes were solved. In both our NMR 
experiments and in the X-ray structures, the H2-Dd α2-1 helix and the CD8 recognition loop 
of the α3 domain are in direct contact with the TAPBPR TN (N/IgV) and TC (IgC) domains, 
respectively (Fig. 2E–G). The TAPBPR TC domain is nestled between the H2-Dd α3 domain 
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and β2m, an unanticipated result, which is supported by our NMR experiments (Fig. 2E–F). 
Detailed inspection of MHC-I/TAPBPR contacts within 4 Å in the X-ray structure shows 
excellent agreement with MHC-I residues undergoing significant chemical shift 
perturbations in solution (Fig. 2G). Thus, independent characterization of the MHC-I/
TAPBPR complex crystallographically and by NMR reveals a multifaceted interaction of 
TAPBPR with both peptide-deficient as well as peptide-loaded MHC molecules.
Modulation of dynamics in MHC-I/TAPBPR complexes
Electron density corresponding to peptide atoms is completely missing from the available 
MHC-I/chaperone structures 19,20,23. To elucidate how peptides influence groove dynamics, 
we compared the spectra of either peptide-deficient, partially loaded or fully loaded MHC-I/
TAPBPR (Fig. 3A). While in the fully loaded complex most methyls in the H2-Dd groove 
give rise to well-resolved NMR peaks, in the other complexes several resonances are 
broadened due to conformational exchange at the intermediate (μs-ms) timescale (Fig. 3A, 
B, left). Notably, when the groove is partially occupied by a disulfide-conjugated pentamer 
peptide, resonances corresponding to residues in the A-, B-, C- and D-pockets become 
consistently less broadened, relative to the unoccupied state, while resonances corresponding 
to residues in the F-pocket remain exchange-broadened (Fig. 3A, B, middle). This ‘rescuing’ 
of attenuated NMR peaks becomes even more pronounced in a complex that is loaded with 
the full-length P18-I10 peptide, specifically for resonances corresponding to F-pocket 
residues (Fig. 3A, B, right). Pairwise comparisons of methyl chemical shift deviations, 
computed relative to the free pMHC-I reference spectrum, show close agreement between 
MHC-I/TAPBPR complexes containing different peptides (Supplementary Fig. 12). A 
difference can be observed at residue I124 (Supplementary Fig. 12, right), which we 
attribute to modulation of dynamics in the α2-1 helical segment when the adjacent F-pocket 
is unoccupied (RGPGC) or occupied (P18-I10) by peptide (Fig. 3B). Analysis of Cα 
distances between representative residues in MD simulations (Online Methods) reveals that 
the peptide-deficient groove undergoes a larger range of motions, relative to the fully loaded 
MHC-I molecule and the chaperoned peptide-deficient groove, an effect which becomes 
more pronounced at the C-, E- and F-pockets, near the α2-1 helix (Fig. 3C). Taken together, 
our results suggest that both TAPBPR and incoming peptides dampen dynamics in the 
MHC-I groove, culminating in a conformational change within the α2-1 helix.
NMR reveals a peptide-bound intermediate during exchange
To probe conformational intermediates along the TAPBPR-mediated peptide exchange 
pathway, we titrated P18-I10 peptide into a peptide-deficient MHC-I/TAPBPR complex. 
Initially, specific NMR resonances of residues in the H2-Dd groove are attenuated in the 
absence of peptide, while those of residues in the α3 domain remain observable 
(Supplementary Fig. 13A, blue, B–D). Upon the addition of sub-stoichiometric amounts of 
P18-I10, several exchange-broadened NMR resonances begin to appear in either similar 
(V76) or unique (I124, I142, A153, A158) chemical shift positions, relative to the reference 
spectrum of the native P18-I10/H2-Dd/hβ2m molecule (Supplementary Fig. 13A, purple). 
This suggests the formation of a peptide-bound intermediate state. As peptide is 
incrementally added to achieve a 1:1 molar ratio, the new resonances observed for several 
methyls (I124, I142, V231) are shifted and attenuated, while a set of resonances 
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corresponding to the chemical shifts of the native pMHC-I reference can be simultaneously 
observed (Supplementary Fig. 13A, orange and green). The “transient” methyl resonances 
likely arise from an averaging of multiple conformations with distinct chemical shift 
environments. Their remission into the intermediate exchange NMR regime with increasing 
peptide concentration and consequent broadening is attributed to a phenomenon previously 
described as “transient narrowing” 30. A complementary LC-MS analysis unambiguously 
confirms that the “transient” resonances correlate with the formation of an intermediate state 
of the MHC-I/TAPBPR complex with peptide captured in the MHC-I groove. Finally, 
titration of 6-fold molar excess of P18-I10 peptide leads to recovery of the reference 
spectrum, as expected for the formation of the native free pMHC-I species in equilibrium 
with the TAPBPR-bound form (Supplementary Fig. 13A, red). The same trend is observed 
when P18-I10 is titrated onto RGPGC/H2-Dd S73C/hβ2m/TAPBPR complex, where the 
addition of the mild reducing agent tris(2-carboxyethyl) phosphine (TCEP) allows for 
complete annealing of P18-I10 and subsequent TAPBPR dissociation (Supplementary Fig. 
14).
In addition, we compared binding of a sub-optimal peptide (photoP18-I10) to the peptide-
deficient MHC-I/TAPBPR. PhotoP18-I10 utilizes the same N- and C-terminal anchors as the 
native P18-I10, but shows a reduced thermal stability in the pMHC-I (Supplementary Table 
1), presumably due to steric hindrance of the bulky 2-nitrophenyl group and β-amino acid 
backbone relative to the native valine sidechain at position 8 6,31 (Supplementary Fig. 15). In 
contrast to P18-I10, photoP18-I10 does not promote TAPBPR dissociation from the MHC-I, 
even at large molar excess (Supplementary Fig. 15). Taken together, our NMR data suggest 
that the peptide-deficient MHC-I groove in complex with TAPBPR is sampling multiple 
conformations, relevant for both peptide recognition and TAPBPR release. Binding of 
peptide to the empty groove results in the formation of a distinct TAPBPR-bound 
intermediate state, consistent with our NMR results using purified complexes (Fig. 2A–C).
Negative allosteric coupling between peptide and TAPBPR
To identify peptide features that promote chaperone dissociation, we first screened a range 
of N- and C-terminal truncations for their efficiency at rescuing the thermal stability of free 
peptide-deficient MHC-I molecules prepared using conditional ligands 6,20,31. Examining 
binding of N- and C-terminal deletions of the native ligand P18-I10, we find that a single N-
terminal deletion (ΔR1 - GPGRAFVTI) can modestly rescue H2-Dd thermal stability with a 
resulting Tm of ~44°C (Supplementary Table 1, Fig. 4A). The reduced stability is attributed 
to the loss of Arg1 contacts with Tyr7, Tyr171 and Glu163 in the A and B-pocket of H2-Dd, 
resulting in a reduced affinity (Supplementary Fig. 16A–C and Supplementary Table 2). We 
next used a fluorescence anisotropy (FA) assay to test binding of different peptides to a 
chaperoned MHC-I 5,6,32,33. We offered graded concentrations of peptide-deficient MHC-I/
TAPBPR complex to 0.75 nM of a fluorescently labeled peptide (TAMRA-P18-I10), which 
is readily captured in the MHC-I groove. (Supplementary Fig. 17A). We find that an excess 
of 10 μM P18-I10 completely outcompetes TAMRA-P18-I10 for binding to empty groove 
(Supplementary Fig. 17B). Finally, we compared P18-I10, photoP18-I10, GPGRAFVTI, 
using a similar competition assay. Our results, in terms of the apparent dissociation constants 
of 0.09, 0.38 and 130 μM, suggest that peptide/MHC-I interactions spanning the entire 
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groove are critical for TAPBPR-mediated peptide exchange (Fig. 4B). In both the DSF an 
FA assays, a negative control peptide, FVTI, shows minimal stability and exchange, as 
expected. Our FA results are also consistent with surface plasmon resonance (SPR) 
experiments, where addition of P18-I10 leads to a significant increase in the dissociation rate 
of TAPBPR from the peptide-occupied groove, relative to a peptide-deficient molecule (koff 
< 0.002 s−1). Addition of the sub-optimal GPGRAFVTI peptide leads to a more modest 
effect (Fig. 4C, Supplementary Fig. 17C, D).
To further explore how peptides of different lengths may trigger TAPBPR release from the 
complex, we performed a series of NMR titrations. For P18-I10, we detect the formation of 
an intermediate state at a 1:1 molar ratio, highlighted by the appearance of methyl 
resonances corresponding to unique Ile124 and Ile142 conformations (Fig. 4D, green, red 
dotted boxes), while six-fold molar excess of peptide results in detectable formation of the 
free pMHC-I (Fig. 4D, red). Similarly, a titration of GPGRAFVTI shows the intermediate 
resonances, albeit with significantly attenuated intensities relative to P18-I10, as shown by a 
comparison of 1H slices, (Fig. 4E, green). Accordingly, formation of the final pMHC-I is not 
detectable by our NMR methyl probes using up to 20-fold molar excess of GPGRAFVTI 
(Fig. 4E, red). A combined NMR, SPR and FA analysis allows for a thorough description of 
the TAPBPR peptide-exchange cycle (Supplementary Fig. 18). According to our model, 
stable capture of a high-affinity peptide in the MHC groove can lead to as much as a three-
order of magnitude increase in the dissociation rate of TAPBPR, from 0.002 s−1 to 2.9 s−1, 
as observed for P18-I10 (Supplementary Table 3). Notably, different peptides show a range 
of off-rates from the chaperoned MHC groove, from approx. 0.1 s−1 for P18-I10, to >2 s−1 
for the N-terminal deletion mutant.
Finally, to examine specific structural adaptations that occur upon peptide annealing to the 
chaperoned groove, and their role in peptide exchange, we compared methyl NMR spectra 
of the “stalled” complex containing GPGRAFVTI relative to the free P18-I10/H2-Dd. 
Despite the missing N-terminal Arg from the GPGRAFVTI peptide, we measure small 
CSDs (< 0.1 ppm) for NMR peaks corresponding to residues in the A- and B-pockets, in 
contrast to the significant CSDs (0.1 to 0.3 ppm) for peaks corresponding to a continuous 
surface along the N-terminal α2-1 helical segment (residues 138–152) (Fig. 4F). This 
suggests that the conformation of the chaperoned MHC-I groove in the “stalled” complex is 
similar to the native molecule, with the exception of residues in the D-, E- and F- pockets. 
This finding is consistent with the sampling of multiple α2-1 helix conformations in fast 
exchange while the peptide is bound to the MHC-I/TAPBPR complex, where the ensemble 
average is skewed towards the “open” state observed both in the X-ray structure of 
TAPBPR-bound MHC-I and in our MD simulations (Supplementary Fig. 16C, D, F, red 
arrows). Taken together, our results support the view that the chaperoned MHC-I groove 
selectively captures incoming peptides and specific structural adaptations are required for 
TAPBPR dissociation and formation of the final pMHC-I product (Fig. 4A, Supplementary 
Table 1). TAPBPR release from the complex is driven by negative allosteric coupling 
between the peptide binding sites at both ends of the MHC-I groove, the TAPBPR binding 
site near the α2-1 helix and the anti-parallel pleated β-sheet underpinning the groove (Fig. 
4F).
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The chaperoned groove recognizes peptides in their native conformation
We next titrated 13C labeled peptides onto unlabeled, peptide-deficient MHC-I/TAPBPR 
complexes to explore peptide annealing under conditions where TAPBPR dissociation from 
the MHC-I is negligible (according to our previously determined Kd of 32 μM). We find that 
13C methyl and aromatic resonances of P18-I10 show large CSDs when the free peptide is 
compared to MHC-I and MHC-I/TAPBPR bound states (Fig. 5A, B). P18-I10 binds in slow 
exchange, where a unique set of peaks corresponding to formation of the pMHC-I/TAPBPR 
complex can be readily observed. TAPBPR binding only leads to minor additional changes, 
suggesting that chaperones do not alter the conformation of the MHC-I bound peptide (Fig. 
5A–C). As expected, we observe significantly reduced binding for 13C-labelled 
GPGRAFVTI peptide, albeit still at the slow exchange NMR regime (Supplementary Fig. 
19A, B), as highlighted by a peak intensity ratio analysis for all peptide methyl probes 
obtained at the 1:1 titration point (Fig. 5D). A detailed NMR line shape analysis suggests 
binding to be at least 100-fold weaker than P18-I10 (>900 μM vs 7.2 μM, respectively, Fig. 
5E and Supplementary Fig. 19D). The slow exchange NMR titration behavior observed for 
GPGRAFVTI, despite its modest affinity, suggests that peptide binding necessitates kon-
limiting structural adaptations in an “induced fit” mechanism 34. The resonances of the 
bound states are consistent between P18-I10 and GPGRAFVTI, showing that the two 
peptides adopt a similar conformation in the intermediate complex with TAPBPR, relative to 
the reference pMHC-I structure (Supplementary Fig. 19, Supplementary Fig. 20, 
Supplementary Table 4).
DISCUSSION
Despite tapasin and TAPBPR having been discovered more than a decade ago, only recently 
have structural and mechanistic details of their peptide editing function begun to emerge 
13,15
. Here, we use solution NMR to directly evaluate the role of structure and dynamics in 
mediating peptide exchange. In agreement with the recent X-ray structures 19,20, conserved 
surfaces on the H2-Dd heavy chain, including the pleated β-sheet floor of the groove, the 
α2-1 helix, and the CD8 recognition loop in the α3 domain are utilized to form a high-
affinity interaction with TAPBPR (Fig. 2E–G). Our data further highlight effects on the α1 
helix, opposite from the TAPBPR binding site (Supplementary Fig. 5E, F and 
Supplementary Fig. 6E, F), which further supports a widening of the MHC-I groove at the F-
pocket (Supplementary Fig. 16C–F). The widening is promoted by a “Tyr84 swing”, where 
the conserved heavy chain residue Y84 is flipped and hydrogen bonds with TAPBPR E102 
19,20
. In the absence of TAPBPR, Y84 plays a role in closing of the α2-1 helix “latch” by 
associating with the C-terminus of bound peptides in the F-pocket 35. This phenomenon is 
similar to a “W43 swing”, mediating class II MHC interaction with the DM chaperone 36. 
Together, our independent studies of the MHC-I/TAPBPR complex by crystallography and 
solution NMR allow us to elucidate a detailed mechanism of peptide exchange.
Conformational plasticity within the groove of class I and II MHC molecules has been 
linked to peptide exchange 21,22. NMR has provided direct measurements of groove 
dynamics in peptide-deficient molecules 37, as well as domain mobility along the β2m 
interface 38. NMR relaxation dispersion experiments have revealed dynamics of the α2-1 
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helix and pleated β-sheet of peptide-loaded molecules, such as HLA-B*35:01 39, while 
hydrogen/deuterium exchange points to allotype-specific differences in dynamics between 
peptide-loaded and peptide-deficient MHC-I molecules 40. Our relaxation dispersion 
measurements of pMHC-I highlight motions at the α2-1 helix and pleated β-sheet floor of 
H2-Dd (near the C-, E- and F-pockets), and structural plasticity at the hβ2m/heavy chain 
interface (Fig. 1D), consistent with previous NMR results for HLA-B*27 38,41 and 
molecular dynamics simulations of HLA-B*44 42. Intriguingly, regions of mobility in the 
pMHC-I correlate with surfaces required for TAPBPR binding (Supplementary Fig. 1), 
suggesting a direct role of dynamics in driving chaperone recognition. In particular, the Cβ 
methyl of A150, which is located on a linker region between the short α2-1 and longer α2-2 
helices, undergoes chemical exchange at the ~2 msec timescale, which could arise from a 
switching between distinct ϕ/ψ dihedral angles impacting the orientation of the α2-1 helix 
(Fig. 1B). In our MD simulations, sampling of the “open” conformation is observed for a 
high-affinity P18-I10/H2-Dd complex, but becomes more pronounced for a peptide-deficient 
molecule (Fig. 3C and Supplementary Fig. 16E, F), consistently with similar simulation 
results reported for other MHC-I alleles 43. Therefore, in conjunction with previous reports 
our data are consistent with a conformational selection mechanism driving the recognition of 
different pMHC-I molecules by TAPBPR.
Our NMR data provide evidence that peptide-deficient MHC-I/TAPBPR complexes are 
stable, properly conformed molecules in solution (Fig. 3A), in agreement with previous 
studies describing the stabilization of chaperoned MHC-I molecules in a peptide-receptive 
conformation 5,6. According to our MD simulations, TAPBPR stabilizes the peptide-
deficient groove by dampening dynamics within the C-, E- and F-pockets relative to an 
empty, unchaperoned MHC-I groove (Fig. 3C and Supplementary Fig. 16E, F), as previously 
suggested by simulations of modeled MHC-I/tapasin complexes 44. Taken together, our 
results suggest a functional role of chaperones as “stand-ins” for the peptide in modulating 
MHC-I groove dynamics, allowing for enhanced kinetic and thermal stability 45.
The available structures of MHC-I/chaperone complexes entirely lack electron density 
corresponding to peptide 19,20,23. Here, we identify a peptide-bound MHC-I/TAPBPR 
intermediate state, and characterize structural adaptations in the MHC-I upon peptide 
annealing to the complex. Dynamics in the MHC-I groove are progressively reduced as a 
function of increasing peptide occupancy (Fig. 3A, B). We further uncover a link between 
crucial contacts in the A- and B-pockets with recognition and modulation of dynamics 
within the chaperoned MHC-I groove, and subsequent TAPBPR dissociation (Fig. 4E and 
Fig 5F). Our data provide evidence for negative allosteric coupling between the A- and F-
pockets of the MHC-I groove, with the TAPBPR binding site near the α2-1 helix and the 
pleated β-sheet underlying the groove. Here, the TAPBPR-induced widening of the MHC-I 
groove, limits peptide binding to the F-pocket (Fig. 4F and Supplementary Fig. 16C, D, F). 
Consequently, while TAPBPR is bound to the MHC-I, initial peptide annealing is dominated 
by interactions within the A- and B-pockets, which remain properly conformed in the 
chaperoned groove. This “indirect” peptide sensing model utilized by chaperones is 
supported by the significantly reduced binding to peptide-deficient H2-Dd/TAPBPR 
observed for GPGRAFVTI lacking critical A- and B-pocket contacts. Notably, a similar 
peptide-editing mechanism has been observed for the DM chaperone, which induces 
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structural rearrangements at the P1 pocket of empty MHC-II molecules to promote the rapid 
and specific selection of high-affinity peptides 36. A putative role for direct peptide sensing 
by TAPBPR via the ‘scoop’ loop spanning residues 22–26 (absent from tapasin), for which 
electron density is present in the H2-Db/TAPBPR but not in the H2-Dd/TAPBPR X-ray 
structure 19,20, has been hypothesized, but such effects remain to be rigorously tested in 
future experiments.
Our results outline a cycle of peptide-exchange governed by reversible transitions between 
ensembles of MHC-I states (Fig. 6A, Supplementary Fig 21A). Sampling of open and closed 
conformations at the α2-1 helix together with dynamics at the heavy chain/β2m interface 
regulates chaperone association and dissociation. Through subtle structural adaptations in 
the MHC-I groove, TAPBPR shifts the binding free energy landscape of the cellular peptide 
pool by several orders of magnitude, as illustrated by our results for the H2-Dd system (Fig. 
6B). In the ER and Golgi, TAPBPR associates with MHC-I molecules to maintain them in a 
receptive conformation (Fig. 6C–F, Step 1). The α2-1 helix ‘latch’ remains in a dynamic 
equilibrium between open and closed conformations while bound to the chaperone (Fig. 6C–
F, Step 1). TAPBPR performs its peptide editing function by promoting dissociation of low 
and moderate affinity peptides, thereby preferentially selecting peptides with higher 
affinities for the chaperoned groove. Low-affinity peptides are completely excluded from the 
MHC-I/TAPBPR complex (Fig. 6C, Steps 2 and 3). Moderate-affinity peptides interact 
transiently with the MHC-I/TAPBPR complex, but fail to promote TAPBPR release due to 
the lack of crucial A-, B-pocket contacts, which limits the lifetime within the chaperoned 
groove (fast koff) (Fig. 6D, Steps 2 and 3, Supplementary Fig. 21B). In contrast, high-affinity 
peptides are guided by initial contacts spanning both the A- and F-pockets to form a 
prolonged interaction within the groove, resulting in a closure of the α2-1 helix ‘latch’, 
which triggers TAPBPR release from the pMHC-I (Fig. 6E, step 3). Inside the ER, a 
competition between these processes occurs simultaneously, where high-affinity peptides are 
maintained within the chaperoned groove to become part of the displayed antigen repertoire. 
(Fig. 6F, step 3).
In summary, we provide a detailed NMR characterization of dynamics of empty and peptide-
loaded MHC-I/TAPBPR complexes and elucidate structural adaptions upon formation of a 
peptide-bound intermediate state in relation to peptide exchange. The shared similarities of 
structural and functional aspects between TAPBPR and tapasin implies that a similar 
exchange mechanism is utilized by tapasin in the peptide-loading complex, a hypothesis that 
can be readily tested. Future studies on other H2 and HLA alleles with model peptides will 
expand upon the role of conformational dynamics and allosteric communication in shaping 
the peptide editing functions of these highly efficient molecular machines.
ONLINE METHODS
Protein expression, refolding and purification
DNA encoding the luminal domain of class I MHC (MHC-I) heavy chains H2-Dd, HLA-
A*01:01, HLA-B*15:01, HLA-B*27:02 and human β2m (hβ2m, light chain) were provided 
by Dale Long of the NIH Tetramer Core Facility and transformed into Escherichia coli 
BL21(DE3) (Novagen). Proteins were expressed in Luria-Broth and inclusion bodies were 
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processed as previously described 46. For in vitro refolding, 10 mg of peptide and 200 mg 
mixtures of heavy chain:light chain at a 1:3 molar ratio were slowly diluted over 24 hours 
into refolding buffer (0.4 M Arginine-HCl, 2 mM EDTA, 4.9 mM reduced L-glutathione, 
0.57 mM oxidized L-glutathione, 100 mM Tris pH 8.0) at 4°C while stirring. Refolding 
proceeded for four days at 4°C without stirring. Samples where photoP18-I10 was used were 
protected from light (except during UV-irradiation) with aluminum foil throughout 
purification and data acquiring procedures. Purification of pMHC-I complexes was 
performed by size exclusion chromatography (SEC) with a HiLoad 16/600 Superdex 75 pg 
column at 1 mL/min with running buffer (150 mM NaCl, 25mM Tris pH 8), followed by 
anion exchange chromatography with a mono Q 5/50 GL column at 1 mL/min using a 40 
minute 0–100% gradient of buffer A (50 mM NaCl, 25mM Tris pH 8) and buffer B (1M 
NaCl, 25mM Tris pH 8). The luminal domain of TAPBPR was expressed as previously 
described using a Drosophila S2 cell expression system and purified in a similar manner to 
pMHC-I molecules 47. The C121S and S73C H2-Dd mutants were generated by site directed 
mutagenesis and confirmed with DNA sequencing. Refolding and purification of 
RGPGC/H2-Dd S73C/hβ2m was performed with all buffers contained 1 mM dipeptide (Gly-
Leu) to improve stability throughout sample preparation. All proteins were exhaustively 
buffer exchanged into 100 mM NaCl, 20 mM sodium phosphate pH 7.2. Protein 
concentration was determined using A280 measurements on a NanoDrop with extinction 
coefficients estimated with the ExPASy ProtParam tool.
Peptides and mass spectrometry
Unlabeled peptides (≥ 98% purity) were prepared by chemical synthesis (Biopeptik Inc, 
Malvern, USA or GenScript, Piscataway, USA). The UV-labile RGPGRAFJ*TI, referred to 
as photoP18-I10, was derived from P18-I10 (RGPGRAFVTI) 6 and contains a modification 
with 3-amino-3-(2-nitrophenyl)-propionic acid (J*). The reducing agent labile RGPGC, also 
derived from P18-I10, contains a modification with a cysteine at position five and truncation 
of residues A6-I10. Peptide concentration was determined using measurements of A205 with 
a NanoDrop with extinction coefficients determined using the Protein Parameter Calculator 
by Anthis and Clore. Liquid chromatography-mass spectroscopy (LC-MS) was carried out 
with passage through a Higgins PROTO300 C4 column (5 μm, 100 mm x 2.1 mm) followed 
by electron ion spray mass spectroscopy performed on a Thermo Finnigan LC/MS/MS 
(LTQ). Analysis and deconvolution of LC-MS data was performed with MagTran.
Isotopically labeled peptides were prepared with DNA sequences corresponding to P18-10 
(RGPGRAFVTI) or GPGRAFVTI as fusions with an N-terminal immunoglobulin-binding 
domain of streptococcal protein G (GB1) and a His6 tag subcloned in pET22b vector. For 
expression, Escherichia coli BL21(DE3) (Novagen) cells were transformed with plasmid and 
grown at 37°C in 1× M9 minimal media for U-[15N, 13C] labeling following standard 
protocols. Expression proceeded with the addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 37°C, 200 r.p.m. for 5 hours. Cell extract was passed 
through a FF-HisTrap Column (GE Healthcare) and then His6-GB1-peptide construct was 
solid phase extracted using a Strata C-18T column (Phenomenex). The protein was 
resuspended in 50% (v/v) trifluoroacetic acid to perform cyanogen bromide (100-fold molar 
excess relative to the methionine molar concentration) cleavage overnight. Cleaved peptide 
McShan et al. Page 11
Nat Chem Biol. Author manuscript; available in PMC 2019 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
was purified by reversed phase chromatography using an Aeris PEPTIDE XB-C18 column 
(3.6 μm, 150 x 4.6 mm, Phenomenex). Peptide identity and purity (≥ 98% purity) was 
confirmed by mass spectrometry.
Fluorescence Anisotropy
Fluorescence anisotropy (r, herein referred to as FA) was performed using a P18-I10 peptide 
labeled with TAMRA dye (KTAMRAGPGRAFVTI, herein called TAMRA-P18-I10) 
(Biopeptik Inc, Malvern, USA), which was modeled to not disrupt essential interaction with 
MHC-I residues compared to the native Arg1. Peptide-deficient H2-Dd/hβ2m/TAPBPR 
complexes for FA were prepared by UV-irradiation at 365 nm for 1 hour of photoP18-
I10/H2-Dd/hβ2m/TAPBPR complexes as described below. For association experiments, 
graded concentrations (up to 800 nM) of peptide-deficient H2-Dd/hβ2m/TAPBPR was added 
to 0.75 nM TAMRA-P18-I10. For P18-I10 competition experiments, a mixture of 250 nM 
peptide-deficient H2-Dd/hβ2m/TAPBPR complex and 0.75 nM TAMRA-P18-I10 was 
offered graded concentrations of native P18-I10 ranging from 0 to 75 μM. Additional 
peptide competition assays were performed using the same parameters except by adding 
graded concentrations ranging from 0 to 75 μM of different peptides (GPGRAFVTI, 
photoP18-I10, FVTI). All FA experiments were performed in the dark to protect the 
TAMRA-P18-I10 and photoP18-I10 peptides from photolysis. In the competition 
experiments, the average of FA after incubation with 250 nM peptide-deficient H2-Dd/hβ2m/
TAPBPR for 95–105 minutes at room temperature was plotted as a function of the log10 of 
excess peptide. Each experiment was performed at room temperature in a volume of 100 μL 
and loaded onto a black 96-well polystyrene assay plate (Costar 3915). FA data was 
recorded via a Perkin-Elmer Envision 2103 plate reader with excitation filter λex = 531 nm 
and emission filter λem = 595 nm. Each experiment was performed in triplicate and is 
representative of at least two independent experiments. Experimental values were subtracted 
from background FA values obtained from incubation of TAMRA-P18-I10 alone. All 
samples were prepared in matched buffer (100 mM NaCl, 20 mM sodium phosphate pH 7.2, 
0.05% (v/v) tween-20). FA time courses were analyzed by global fitting to the 4-step using 
DynaFit.
Differential scanning fluorimetry
DSF experiments were performed on an Applied Biosystems ViiA 7 qPCR machine with 
excitation and emission wavelengths set to 470 nm and 569 nm with proteins in buffer of 
100 mM NaCl, 20 mM sodium phosphate pH 7.2. Experiments were conducted in triplicate 
in MicroAmp Fast 96-well plates with 50 μL total volume containing final concentrations of 
7 μM protein and 10× SYPRO orange dye (ThermoFisher). For UV-treated samples, proteins 
were UV-irradiated at 365 nm for 1 hour at room temperature and assayed following 
centrifugation at 13,000 rpm for 10 minutes to remove precipitates. For reducing agent 
treated samples, samples were incubated with 1 mM TCEP for 1 hour and assayed in the 
presence of TCEP, following centrifugation at 13,000 rpm for 10 minutes to remove 
precipitates. Rescue experiments were performed by incubation with 20-fold molar excess 
peptide throughout the duration of the experiment. Temperature was incrementally increased 
at a scan rate of 1°C/min between 25°C and 95°C. Data analysis and fitting was performed 
in GraphPad Prism v7.
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Preparation of MHC-I/TAPBPR complexes and binding assays
To prepare peptide-deficient MHC-I/TAPBPR complexes, 200 μM photoP18-I10/H2-Dd/
hβ2m and ~200 μM TAPBPR were mixed together (1:1 molar ratio) and incubated for 1 hour 
at room temperature. The mixture was UV-irradiated at 365 nm for 1 hour followed by 
centrifugation at 13,000 rpm for 10 minutes to remove precipitates. Pure 1:1 stoichiometric 
MHC-I/TAPBPR complexes were isolated by SEC with a Superdex 200 Increase 10/300 GL 
column at flow rate 0.5 mL/min in 100 mM NaCl, 20 mM sodium phosphate pH 7.2. For 
analytical SEC binding assays, 80 μM pMHC-I and 160 μM TAPBPR were mixed (1:2 
molar ratio) and incubated at room temperature for 1 hour. Analytical SEC binding assays 
were performed using a Superdex 200 Increase 10/300 GL column at flow rate 0.5 mL/min 
in 100 mM NaCl, 20 mM sodium phosphate pH 7.2.
Surface plasmon resonance
SPR measurements were performed using a BiaCore T200 (GE Healthcare, Uppsala, 
Sweden) instrument at 25°C in 150 mM NaCl, 10 mM HEPES pH 7.3, 3 mM EDTA, 0.05% 
(v/v) tween-20. Approximately 300 resonance units (RU) of biotinylated TAPBPR was 
immobilized on a streptavidin-coated chip (GE Healthcare). H2-Dd S73C/β2m was then 
captured on the TAPBPR coated surface followed by a 120 second wash-out step with 
buffer. Graded concentrations of P18-I10 or GPGRAFVTI ranging from 0.5 to 32 μM were 
sequentially injected for 120 seconds and the dissociation of H2-Dd S73C/β2m was 
monitored. The surface was regenerated after each binding and dissociation cycle by 
injecting 100 μM P18-I10 to achieve complete dissociation.
Sample preparation for NMR
Samples for NMR were prepared as previously described 48. Protein expression was 
achieved by induction with 1 mM isopropyl-D-thiogalactoside (IPTG) at an OD600 of 0.6 
followed by cell growth at 37°C for 5 hours at 200 r.p.m. Isotopically labeled pMHC-I was 
buffer exchanged into 100 mM NaCl, 20 mM sodium phosphate pH 7.2, 0.01% (v/v) NaN3 
and 1 U Roche protease inhibitor cocktail in 90% H2O/10% D2O. MHC-I/TAPBPR 
complexes for NMR were prepared by mixing 200 μM isotopically labeled pMHC-I with 
200 μM unlabeled TAPBPR at a 1:1 mole ratio in matched buffer (100 mM NaCl, 20 mM 
sodium phosphate pH 7.2) followed by isolation of pure 1:1 complex by SEC as described 
above. Peptide-deficient complexes were prepared as described above using isotopically 
labeled pMHC-I samples followed by isolation of pure 1:1 complex by SEC. Loss of peptide 
was confirmed by LC-MS.
NMR chemical shift assignments and dynamic measurements
Triple-labeled U-[15N, 13C, 2H] and AILV sidechain methyl (Ala 13Cβ, Ile 13Cδ1, Leu 
13Cδ1/13Cδ2, Val 13Cγ1/13Cγ2) labeled (at either H2-Dd or hβ2m) pMHC-I molecules were 
prepared. We utilized a previously published multipronged assignment approach 48. 
Backbone amide resonances were assigned using a standard TROSY-based 3D HNCO, 
HNCA and HN(CA)CB experiments recorded at 600 MHz at 25°C. Acquisition times of 30 
msec (15N), 20 msec (13CO) and 10/5 msec (13Cα/13Cβ) in the indirect dimension were 
used. Backbone amide assignments were validated by acquiring amide-amide NOEs using 
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3D HN-NHN and 3D N-NHN SOFAST NOESY experiments 49. AILV methyl resonances 
were assigned using a 3D HMCM[CG]CBCA methyl out-and-back experiment recorded on 
1 mM pMHC-I samples at 800 MHz at 25°C. Acquisition parameters were 80, 80, 1,536 
complex points in the 13Caliphatic, 13CM, 1HM dimensions corresponding to acquisition times 
of 4, 10 and 69 msec. A relaxation delay of 1.5 seconds was used with 40 scans/FID. 
Chemical shifts observed in the 3D HMCM[CG]CBCA experiment were compared to 13Cα 
and 13Cβ chemical shifts from 3D HNCA and 3D HN(CA)CB experiments. AILV methyl 
assignments were validated and stereo-specifically disambiguated by acquiring methyl-
methyl NOEs with 3D HM-CMHM and 3D CM-CMHM SOFAST NOESY experiments 48. All 
3D SOFAST NOESY experiments were acquired with standard parameters as previously 
described 47 on 1 mM pMHC-I samples with a relaxation delay (d1) of 0.2 sec and an NOE 
mixing time (d8) of 0.3 sec. To confirm the assignment of the TAPBPR bound pMHC-I 
states for the backbone amide and sidechain methyl resonances, additional 3D HM-CMHM 
and 3D HN-NHN SOFAST NOESY experiments were acquired on a 200 μM pMHC-I/
TAPBPR complex and compared to similar NOE strips from the unbound pMHC-I 
reference. All NMR data was processed with NMRPipe 50 and analyzed using NMRFAM-
SPARKY 51.
Backbone 15N amide relaxation rates were determined using TROSY-readout R1, R1ρ and 
15N-{1H} heteronuclear NOE experiments at 25°C recorded at 1H field of 600 MHz on 1 
mM perdeuterated pMHC-I samples. R2 rates were obtained from rotating frame R1ρ rates 
measured under a spin-lock field strength of 2 kHz. AILV methyl sidechain relaxation rates 
were determined using 1H-13C multiple quantum Carr-Purcell-Meiboom-Gill (CPMG) 
relaxation dispersion experiments on 1 mM perdeuterated pMHC-I samples recorded at 
25°C at 600 MHz. Spectra were recorded in an interleaved manner with CPMG field 
strengths of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 850 and 1000 Hz 
with a constant time delay of 40 msec. Peak intensities were converted to the R2, eff 
transverse decay rates with the equation R2, eff = 1/TCPMG × ln (I0/IνCPMG). CPMG curves 
were analyzed using GUARDD 52.
NMR chemical shift mapping and titrations
Chemical shift deviations (CSD, p.p.m.) were determined using the equations 
ΔδNH=[1/2(ΔδH2+ΔδN2/25)]1/2 for 15N amides and ΔδCH3=[1/2(ΔδH2+ΔδC2/4)]1/2 for 13C 
AILV methyls. The change in peak intensity was determined by calculating the ratio of 
Ibound/Iunbound for each assigned NMR resonance and normalized to the most intense NMR 
peak. For peptide titration experiments, NMR buffer (100 mM NaCl, 20 mM sodium 
phosphate pH 7.2, 10% D2O (v/v), 1U Roche protease inhibitor) matched samples of 200 
μM peptide-deficient H2-Dd/hβ2m/TAPBPR or RGPGC/H2-Dd S73C/hβ2m/TAPBPR 
complexes (labeled at the heavy chain) were titrated with increasing concentrations of 
unlabeled peptide stock with 2D 1H-13C methyl SOFAST HMQC readouts recorded at 25°C 
at a 1H field strength of 800 MHz. Protein:peptide molar ratios were 1:0, 1:0.01, 1:0.03, 
1:0.05, 1:0.1, 1:0.25, 1:0.4, 1:0.7, 1:1, 1:2, 1:3, 1:4, 1:5 and 1:6. At each point, 2D 1H-13C 
SOFAST HMQC spectra were acquired with 136 scans, 0.2 sec recycle delay (d1) and 
acquisition times of 30 msec in the 13C dimension. Titrations of 200 μM peptide-deficient 
H2-Dd/hβ2m/TAPBPR complex (labeled at the heavy chain) with unlabeled photoP18-I10, 
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GPGRAFVTI and FVTI peptides into were performed under similar conditions using 1:0, 1: 
0.25, 1:1, 1:6 and 1:20 protein:peptide molar ratios. All samples used in the titration 
containing photoP18-I10 were protected from light throughout data acquisition.
The titration of TAPBPR onto AILV methyl labeled (at heavy chain) P18-I10/H2-Dd/hβ2m 
was performed on a 100 μM sample in NMR buffer (100 mM NaCl, 20 mM sodium 
phosphate pH 7.2) at the following pMHC-I/TAPBPR ratios: 1:0, 1:0.08, 1:0.2, 1:0.36, 
1:0.52, 1:0.68, 1:0.85, 1:1.16, 1:1.48, 1:1.80, and 1:2.28 with 2D 1H-13C SOFAST HMQC 
spectra as a readout. Data were processed with 4 Hz and 10 Hz Lorentzian line broadening 
in the direct and indirect dimensions, respectively and fit using a two-state model in TITAN 
53
 with bootstrap error analysis of 100 replicas. A total of nine NMR peaks were used for the 
global fitting procedure, including resonances corresponding to methyl groups of residues 
spanning the entire H2-Dd heavy chain (I124, A125, L126, A140, I142, L224, V231, A245, 
V247).
NMR experiments with isotopically labeled peptide
For structure determination of unbound P18-I10 in solution, a sample containing 1 mM P18-
I10 (natural isotopic abundance) was used to record a 2D 1H-1H NOESY (300 msec mixing 
time, 75 msec acquisition time in the indirect dimension) spectrum was acquired at a 1H 
field of 800 MHz at 4°C in addition to 2D 1H-15N HSQC, 2D 1H-13C HSQC spectra, and 
2D 1H-1H TOCSY spectrum (80 msec isotropic mixing time, 30 msec acquisition time in the 
indirect dimension) acquired at a 1H field of 600 MHz at 4°C. In all experiments the recycle 
delay was set to 1 sec. Automatic NOE assignments and structure calculations were 
performed in CYANA 2.1 followed by manual inspection and validation. The P18-I10 
ensemble was generated from the 20 lowest energy structures (1.51 Å RMSD).
NMR spectra of P18-I10 or GPGRAFVTI in the unbound, MHC-I or MHC-I/TAPBPR 
bound states were obtained using 2D 1H-13C SOFAST HMQC experiments with selective 
excitation of either the methyl (13CM-SOFAST HMQC) or aromatic sidechain (13CAro-
SOFAST HMQC) resonances as previously described 48. CSDs and peak intensity ratios 
analysis was performed as described above. For peptide titration experiments, 113.6 μM of 
unlabeled peptide-deficient H2-Dd/hβ2m/TAPBPR complex was titrated with 1.2, 5.7, 28.4, 
79.8, 113.6, 227.2 and 340.8 μM of 13C labeled peptide. Each sample was prepared in 
matched NMR buffer and experiments were acquired with 2D 1H-13C SOFAST HMQC 
experiments using identical parameters with methyl probes as a readout. Experiments were 
performed at 25°C at a 1H field of 800 MHz.
NMR line shape fitting was performed in Integrative Data Analysis Platform (IDAP, 
available from Dr. Evgenii Kovrigin, http://lineshapekin.net/#IDAP) 54. Data were processed 
with an exponential window function with 4 Hz and 10 Hz Lorentzian line broadening in the 
direct and indirection dimensions, respectively. The 13C dimension from 2D 1H-13C 
SOFAST HMQC spectra was extracted, NMR peaks were normalized to unity area, and fit 
to ‘U’ model corresponding to a two-state binding mechanism with an adjustable constant 
vertical offset for each spectrum in MATLAB. Error bar represent noise root-mean-squared 
deviation in each spectrum. NMR line shape fitting allows for estimate for the upper and 
lower bounds for the Kd and Koff.
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An apparent Kd of each peptide for MHC-I/TAPBPR complex was also determined by 
calculating the fraction peptide bound (fb - the intensity of the bound NMR peak divided by 
the sum of the intensities of the bound and free peaks). Titration points were fit to the 
equation:
f b
=
Kd + [Peptide]Total + [Complex]Total − (Kd + [Peptide]Total + [Complex]Total)
2 − 4[Peptide]Total[Complex]Total
2[Peptide]Total
in Mathematica 11 (Wolfram Research, Inc.). The final apparent Kd was determined by 
taking the average of each Kd value determined for NMR peaks corresponding to each AILV 
residue at each titration point (i.e. a global fit).
Molecular Dynamics simulations
All-atom molecular dynamics (MD) simulations in explicit solvent were carried out as 
previously described for MHC-I/tapasin complexes 55 in GROMACS version 5.1.4 using an 
AMBER99SB-ILDN protein forcefield and TPI3P water model. LINCS and SETTLE 
constraint algorithms were used to constrain peptide/protein and water molecules, 
respectively. An integration time step of 4 fsec was used with coordinates output every 10 
psec. Short range interactions were treated with a Verlet cut-off scheme with 10 Å 
electrostatic and van der Walls cutoffs and long-range electrostatics were treated with the 
PME method with a grid spacing of 1.2 Å and cubic interpolation. Periodic dodecahedron 
boundaries were used. The thermodynamic ensemble was nPT where temperature was kept 
constant at 300K by a V-rescale modified thermostat with 0.1 psec time constant and 
pressure was kept constant at 1 bar pressure using an isotropic Berendsen barostat with 0.5 
psec time constant and 4.5 × 10−5 bar−1 isothermal compressibility. X-ray structures served 
as inputs: empty H2-Dd S73C/β2m/TAPBPR (PDB ID 5WER), P18-I10/H2-Dd/β2m (PDB ID 
3ECB) and empty H2-Dd/β2m (PDB ID 3ECB modified such that the atoms corresponding 
to P18-I10 were removed) with missing densities built in using Rosetta. The system was 
solvated to overall neutral charge and contained Na+ and Cl− ions to yield physiological 
concentration of 0.15 M. Final systems ranged from ~95,000 (empty MHC-I) to 196,000 
(empty MHC-I/TAPBPR complex) atoms. Following 500 steps of steepest-descent energy 
minimization, initial velocities were generated at 65 K with linear heating up to 300 K over 
2 nsec. Trajectories for each molecule were acquired for 500 nsec. Heat maps of the variance 
of distances between Cα atoms of pairs of residues spanning the groove were generated 
using the heatmapper plugin in VMD. Structures were extracted after the final 500 nsec 
simulation using VMD.
DATA AVAILABILITY
NMR assignments for the P18-I10 peptide, H2-Dd heavy chain and hβ2m light chain have 
been deposited into the Biological Magnetic Resonance Data Bank (http://
www.bmrb.wisc.edu) under accession numbers 30350, 27248 and 27249, respectively. The 
solution NMR structure of unbound P18-I10 peptide and X-ray structures of RGPGC/H2-
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Dd S73C/hβ2m and RGPGC/H2-Dd S73C/β2m/TAPBPR are deposited in the RCSB Protein 
Data Bank with accession codes PDB ID 6B9K, 5WES and 5WER, respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Heavy and light chain dynamics of free pMHC-I
(A) Backbone dynamics using 15N probes revealed by measurement of 15N-{1H} NOE, R2 
(s−1) and R1 (s−1) values recorded at 25°C at a 1H field of 600 MHz on H2-Dd-labeled P18-
I10/H2-Dd/hβ2m. A diagram of the H2-Dd secondary structure is provided for reference. 
Gray boxes highlight dynamic regions of interest. (B) and (C) Representative relaxation 
dispersion curves highlighting methyl groups undergoing chemical exchange (Rex > 1 s−1) in 
1H-13C multiple-quantum CPMG experiments recorded at 25°C and a 1H field of 600 MHz. 
NMR resonances with measured Rex > 1 s−1 are H2-Dd residues V12, V28, L95, V103, 
L110, L126, A135, A136, A150, L180, L215, L230, L270 and L272, as well as hβ2m 
residues I1, V27, L39, V49, L54, L64, V82 and V85. (D) Residues with NMR resonances 
exhibiting dynamics are indicated on the structure of P18-I10/H2-Dd/β2m (PDB ID 3ECB) 
with select residues from (A, B, C) labeled, except for C-terminal residues K276/E277, 
which are not present in the X-ray structure. (E) The location of all assigned AILV methyl 
probes is mapped on the structure of P18-I10/H2-Dd/β2m (PDB 3ECB).
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Figure 2. NMR characterization of the 87 kDa pMHC-I/TAPBPR complex
Representative selection from 2D 1H-13C HMQC spectra of P18-I10/H2-Dd/hβ2m 13C AILV 
methyl labeled at (A) H2-Dd or (B) hβ2m for unbound (red) and TAPBPR-bound (blue) 
states recorded at 25°C at a 1H field of 800 MHz. (C) Residues with affected methyl 
resonances from (A) and (B) are mapped on the X-ray structure (PDB ID 3ECB), except for 
I92 of hβ2m which is located on the surface opposing H2-Dd. (D) NMR line shape analysis 
of I124 and I142, performed in TITAN (Online Methods), upon titration of TAPBPR on H2-
Dd labeled pMHC-I. See Supplementary Fig. 8A, B. (E) and (F) effects of TAPBPR binding 
to pMHC-I from solution NMR (using both amide and methyl probes) mapped on the X-ray 
structure of H2-Dd S73C/β2m/TAPBPR complex (PDB ID 5WER). MHC-I: (surface 
representation, H2-Dd green; β2m cyan); TAPBPR (cartoon representation, gray). The N-
terminal domain (TN) and C-terminal domain (TC) of TAPBPR are noted. Residues with 
resonances affected in NMR experiments are shown in salmon (H2-Dd) and orange (hβ2m). 
(G) Comparison of MHC-I/TAPBPR contacts within 4 Å in the X-ray structure focusing on 
the H2-Dd α2-1 helix, adjacent to the F-pocket. H2-Dd residues that are in direct contact in 
the X-ray structure and affected in NMR experiments are colored salmon.
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Figure 3. Modulation of dynamics in MHC-I/TAPBPR complexes
(A) Representative selection of 2D 1H-13C HMQC spectra recorded on: peptide-deficient 
H2-Dd/hβ2m/TAPBPR (left), RGPGC/H2-Dd S73C/hβ2m/TAPBPR (middle), and P18-
I10/H2-Dd/hβ2m/TAPBPR (right). Dotted salmon boxes highlight examples of NMR peaks 
for the comparison shown in (B). An overlay of reference spectra of unbound RGPGC/H2-
Dd S73C/hβ2m (middle) and P18-I10/H2-Dd/hβ2m (right) are shown in gray for comparison 
with the TAPBPR complex. See related Supplementary Fig. 12. (B) Comparison of residues 
with attenuated NMR resonances mapped on the X-ray structure of the MHC-I/TAPBPR 
complex (PDB ID 5WER), shown for three different groove occupancies with modeled 
peptide conformations. H2-Dd green; peptide magenta; TAPBPR gray. (C) All-atom 
molecular dynamics simulations (Online Methods) of peptide-loaded MHC-I, peptide-
deficient MHC-I and peptide-deficient MHC-I/TAPBPR complexes. The diagram shows 
color-coded variance (Å2) of Cα-Cα atom distances computed between pairs of residues 
spanning the H2-Dd groove over 50 ns blocks of the simulation. Larger variance (red/white) 
indicates increased dynamics. The residue pairs are noted, which are highlighted on the P18-
I10/H2-Dd X-ray structure with noted peptide binding pockets (right, PDB ID 3ECB).
McShan et al. Page 22
Nat Chem Biol. Author manuscript; available in PMC 2019 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Recognition of different peptide probes by the MHC-I/TAPBPR complex
(A) DSF of UV-irradiated photoP18-I10/H2-Dd/hβ2m incubated with 20-fold molar excess 
of P18-I10 (RGPGRAFVTI), GPGRAFVTI or FVTI. Non-UV-irradiated photoP18-I10/H2-
Dd/hβ2m is shown for reference. See related Supplementary Table 1. (B) FA (r) of 0.75 nM 
TAMRA-P18-I10 as a function competing unlabeled peptide P18-I10, GPGRAFVTI, 
photoP18-I10 or FVTI after incubation with 250 nM peptide-deficient H2-Dd/hβ2m/
TAPBPR for 100 minutes. Fitted K2′ values are 0.186 μM (P18-I10), 0.501 μM (photoP18-
I10), and 86.2 μM (GPGRAFVTI), which are close to values determined from a global fit 
(Supplementary Fig. 17A, B and Supplementary Fig. 18). K2′ for FVTI could not be 
determined. (C) SPR showing the TAPBPR dissociation phase from MHC-I as a function of 
increasing peptide concentration, assuming a single exponential decay model. See related 
Supplementary Fig. 17C, D. (D) and (E) 2D 1H-13C HMQC spectra of H2-Dd labeled 
peptide-deficient H2-Dd/hβ2m/TAPBPR complexes titrated with different peptides. Dotted 
red boxes highlight intermediate state peaks for I124 and I142 with bound peptide. 1H slices 
from the resonance of I124 in the bound state are inlayed for reference. See related 
Supplementary Fig. 17E. (F) Chemical shift deviation (CSD, ΔδCH3, ppm) of H2-Dd groove 
methyls (within 3.5 Å of the peptide) between GPGRAFVTI/H2-Dd/hβ2m/TAPBPR 
complex and free P18-I10/H2-Dd/hβ2m. Color coded CSD effects are plotted on the 
structure of H2-Dd (PDB ID 3ECB), with modeled GPGRAFVTI peptide. The methyl 
resonances of residues V9, A135 and A136 (shown in black) are missing due to 
conformational exchange-induced line broadening in the TAPBPR complex.
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Figure 5. TAPBPR-mediated loading of isotopically labeled peptides
(A) and (B) 2D 1H-13C HMQC spectra of 13C labeled P18-I10 (RGPGRAFVTI) in the free 
(green), H2-Dd/hβ2m bound (red) and H2-Dd/hβ2m/TAPBPR bound (blue) states for (A) 
methyl and (B) aromatic probes. See related Supplementary Fig. 18. Asterisks (*) denote 
alterative conformations observed for V8 methyls. (C) A correlation plot of CSDs (ΔδCH, 
ppm) for free versus MHC-I bound and free versus MHC-I/TAPBPR bound 13C labeled 
P18-I10. (D) Normalized peak intensity ratios for the H2-Dd/hβ2m/TAPBPR and H2-Dd/
hβ2m bound states (IpMHC-I/TAPBPR/IpMHC-I) for P18-I10 (blue) and GPGRAFVTI (teal). 
(E) NMR line shape analysis from the titration of unlabeled peptide-deficient H2-Dd/hβ2m/
TAPBPR complex with 13C isotopically labeled P18-I10. The 1D 13C spectral slices for the 
Cβ of Ala6 at complex:peptide molar ratios of 0.3 (black), 0.45 (red), 0.92 (green), and 1.34 
(blue). Error bar represent noise RMSD in each spectrum. Curves without error bars are the 
best fit of data with the two-state model. The spectral traces were shifted vertically for visual 
clarity and are shown at different scales for each 1D trace. Estimated Kd and koff values are 
7.2 ± 4.1 μM and < 80 s−1 for P18-I10. See related Supplementary Fig. 19D.
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Figure 6. Molecular mechanism of chaperone-assisted peptide exchange
(A) Thermodynamic cycle of TAPBPR-mediated MHC-I peptide exchange. Fitted 
equilibrium values determined from a combined NMR/FA analysis are shown 
(Supplementary Fig. 18). (B) Conceptual example of how TAPBPR may scrutinize the 
peptide repertoire by increasing free binding energy across the cellular pool of candidate 
peptides. (C–F) Peptide dependence on the dissociation of the MHC-I/TAPBPR complex. 
MHC-I molecules are stylized in a cartoon representation as previously used 13. Step 1: 
TAPBPR chaperoned MHC-I molecules are maintained in a peptide-receptive conformation 
and exhibit widespread dynamics (dotted arrows) within the groove. TAPBPR binding 
induces a widening of the MHC-I groove, specifically in the F-pocket near the α2-1 helix, 
which can sample open and closed conformations, serving as a “latch”. Step 2: Association 
of (C) low-affinity peptide (FVTI, orange), (D) moderate-affinity peptide (GPGRAFVTI or 
photoP18-I10, blue) and (E) high-affinity peptide (P18-I10, magenta) with the complex is 
dependent on specific interactions in the A- and F-pockets. Peptides exist in an ‘on’ and 
‘off’ equilibrium (dotted arrows) with the chaperoned groove. Step 3: TAPBPR release 
requires i) sufficient lifetime of the peptide within the groove to modulate the α2-1 helix 
latch and ii) negative allosteric modulation between non-overlapping peptide binding sites in 
the MHC groove and TAPBPR binding sites. See related Supplementary Fig. 21. (F) Step 4: 
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Following dissociation, TAPBPR is recycled and associates with nearby sub-optimally 
loaded or peptide-deficient MHC-I molecules.
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